News Search Results
Feb 27, 2026, 16:30 ET FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD
More news about: Innocan Pharma Corporation
Feb 27, 2026, 16:30 ET FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD
More news about: Innocan Pharma Corporation
Feb 27, 2026, 11:44 ET Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
oral R-MDMA compound for social anxiety disorder with Phase 2a results anticipated this quarter. AtaiBeckley was added to the NASDAQ Biotechnology Index in December following its formation through the merger of atai Life Sciences and Beckley Psytech. A new patent granted in
More news about: Equity Insider
Feb 27, 2026, 10:38 ET Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced a landmark fulfillment agreement with
More news about: Gallant
Feb 27, 2026, 08:11 ET Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 27, 2026, 07:00 ET Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
NESS ZIONA, Israel, Feb. 27, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of
More news about: Matricelf Ltd.
Feb 26, 2026, 19:58 ET Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
/PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering
More news about: Generate:Biomedicines
Feb 26, 2026, 19:00 ET ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
intravenous administrations.About ImmViraImmVira is a clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization
More news about: ImmVira Group
Feb 26, 2026, 18:00 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
information and a PIN allowing them to access the live call. About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 26, 2026, 16:26 ET Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business
of investment in our autonomous labThis year, we will focus Ginkgo's efforts on autonomous labs as the common platform for biotechnology research and invest to extend our current lead in technology. We are currently expanding our frontier autonomous lab in Boston to include over 50 RACs,
More news about: Ginkgo Bioworks
Feb 26, 2026, 15:34 ET Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been
More news about: Neurizon Therapeutics Limited
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Feb 26, 2026, 12:50 ET Cerecin Announces Publication of Clinical Study Demonstrating Promising Results of CER-0001 (tricaprilin) for Rare Pediatric Epilepsy
(DEE).DENVER, Feb. 26, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company developing metabolic drugs for neurological disorders, today announced the publication of a Phase 1/2a clinical study evaluating the investigational
More news about: Cerecin Inc.
Feb 26, 2026, 12:41 ET Greenberg Traurig Prevails for Investor in Oil Terminal Ownership Breach of Contract Suit
resources, financial institutions, health care, hedge funds, hospitality, infrastructure, insurance, media, medical devices, pharmaceutical and biotechnology, real estate, retail, sports, technology and software, telecommunications, transportation, and video games and esports.About Greenberg
More news about: Greenberg Traurig, LLP
Feb 26, 2026, 11:00 ET ARUP Creates Innovation Central Laboratory To Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners
reference laboratory in the U.S., today announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners. The Innovation Central Laboratory will serve as an ecosystem for validating technologies and accelerating next generation
More news about: ARUP Laboratories
Feb 26, 2026, 11:00 ET uniQure N.V. Stock Alert: QURE Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses
investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.
More news about: Robbins LLP
Feb 26, 2026, 10:57 ET Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
Feb 26, 2026, 10:30 ET Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses
purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Robbins LLP
Feb 26, 2026, 10:00 ET Transformative Biotech Names Mark Kelleher, PhD as Executive VP of R&D
reinforcing its commitment to shaping the future of molecular diagnostics.About Transformative Biotech Transformative Biotech is a biotechnology company focused on deploying rapid, highly accurate, and robust, direct-to-PCR technologies with the power to transform molecular testing for infectious
More news about: Transformative Biotech, LLC
Feb 26, 2026, 10:00 ET Monod Bio Announces Appointment of Robert J. Bujarski to Board of Directors
Health Industry Distributors Association (HIDA) Educational Foundation.About Monod BioMonod Bio is a Seattle-based biotechnology company and a spinout from the David Baker Lab at the University of Washington's Institute for Protein Design. The company uses AI-powered de novo
More news about: Monod Bio
Feb 26, 2026, 08:24 ET Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
life sciences and diagnostics innovator. Mr. Beauvalot's roles included vice president and head of business development and strategy for Danaher's biotechnology and genomics business areas. Mr. Beauvalot also served as vice president of strategy and corporate development and vice president of global business
More news about: Quest Diagnostics
Feb 26, 2026, 08:15 ET genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
(Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading
More news about: genOway
Feb 26, 2026, 08:00 ET SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
Feb. 26, 2026 /PRNewswire/ -- SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been selected for Phase 1 of a next-generation vaccine development initiative managed by the European Health and Digital
More news about: SK bioscience
Feb 26, 2026, 07:30 ET Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Feb 26, 2026, 07:00 ET HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
BOSTON, Feb. 26, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced it
More news about: HotSpot Therapeutics